Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 378

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 378
---
 votes equal to the number of shares of common stock into which the preferred stock could be converted on the record date. F-23

LB Pharmaceuticals Inc

Notes to Financial Statements

Upon the closing of the Series C Offering, the Company’s Board of Directors shall consist of no more
than seven members, including: one director shall be designated by each of the Series C New Investors; one director shall be designated by the existing stockholders of the Company, one director shall be the CEO of the Company and one independent
director to be mutually agreed upon.

Series A and Series B Protective Provisions:At any time when shares of Series A or Series B preferred
stock are outstanding, the Company will not, without the consent of a majority of the outstanding shares of Series A and Series B preferred stock (voting together as a single class): (i) take any action that requires the separate approval of the
Series A or Series B preferred stockholders; (ii) amend the Fourth Amended Certificate to adversely affect the rights of the Series A or Series B stockholders differently from the Preferred Stock; or (iii) increase or decrease the
authorized number of Series A or Series B preferred stock.

Series C Protective Provisions: Additionally, at any time that at least 50% of
Series C preferred stock is outstanding, the Company will not without the consent of at least 60% of the Series C preferred stockholders (“Requisite Series C Holders”): (i) liquidate, dissolve or wind up the Company; (ii) amend,
alter, repeal or waive any provisions of the Fourth Amended Certificate of Incorporation provided that any such amendment or waiver that is adverse to any series of Preferred Stock shall require the consent of the affected series (voting separately
as a class); (iii) adversely change the rights, preferences or privileges of the Series C preferred stock; (iv) create any new class or series of equity interest having rights, preferences or privileges senior to or in parity with the Series C
preferred stock; (v) increase or decrease the authorized number of shares of Preferred or Common Stock; (vi) purchase or redeem any Common or Preferred Stock, other than Common Stock granted by Board approved equity compensation
arrangements; (vii) pay or declare any dividends or other distributions on Common or Preferred Stock; (viii) incur any indebtedness in excess of $1 million (other than ordinary trade indebtedness); (ix) increase or decrease the number
of Directors on the Board; or